Please login to the form below

Not currently logged in
Email:
Password:

Lilly/Boehringer diabetes drug approved

The US Food and Drug Administration has granted marketing approval to a type 2 diabetes drug developed through a partnership between Lilly and Boehringer Ingelheim

The US Food and Drug Administration (FDA) has granted marketing approval to a type 2 diabetes drug developed through a partnership between Lilly and Boehringer Ingelheim.

Approval of the drug, Tradjenta (linagliptin), is the first regulatory milestone in the companies' worldwide diabetes alliance since the partnership was formed in January of this year. 

Tradjenta is indicated to lower blood sugar in adults when used in conjunction with a diet and exercise programme. The drug can be used as monotherapy or in combination with other commonly prescribed diabetes medications. 

The therapy increases the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 (DPP-4). It is the first of the DPP-4 inhibitors to be approved at one dosage strength (5 mg, once daily), with no dose adjustment necessary in patients with kidney or liver impairment.

The approval was based on a New Drug Application (NDA) that contained data from eight double-blind, placebo-controlled clinical studies involving about 3,800 patients with type 2 diabetes.

Tradjenta is currently under regulatory review in the EU and Japan. The product will be available as a tablet that can be taken with or without food.

"This approval provides another treatment option for the millions of Americans with Type 2 diabetes," said Mary Parks, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "It is effective when used alone or when added to existing treatment regimens."

4th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

eyeforpharma_h_logo.png
Make Anthill your strategic partner in Barcelona
We are excited to attend and exhibit at eyeforpharma Barcelona 2017 (March 14-16th), and present two multichannel strategy workshops....
Why we need to bring empathy back into medcomms
Medical communications requires you to bring more empathy to your communications...
2016: The year when deal-makers took stock?
Merger-mania and asset swaps slowed and joint ventures were back in fashion...

Infographics